Saratov JOURNAL of Medical and Scientific Research

Eradication therapy in children: the choice of the optimal treatment regimen

Year: 2019, volume 15 Issue: №2 Pages: 225-231
Heading: Pediatrics Article type: Review
Authors: Zryachkin N.I., Ananyeva O.V.
Organization: Saratov State Medical University

The review is devoted to the choice of the optimal treatment regimen of eradication therapy in children. Main tasks in the treatment of children with gastroduodenal pathology associated with Helicobacter pylori are eradication of the pathogen, restoration of the damaged mucosa and prevention of recurrence of the infection. A particular importance in the composition of eradication schemes is the choice of antibacterial drugs. The main requirements for anti-Helico-bacter therapy regimens used in pediatric practice are: eradication rate of at least 80 %, economic accessibility, good tolerability with minimal severity of adverse reactions, optimal frequency of admission. An analysis of a number of domestic and foreign studies has shown that insufcient adherence of the patient to therapy, the presence of antibacterial resistance, pathogenicity factors in a number of strains of H. pylori have a negative efect on the efectiveness of treatment and should also be taken into account when choosing therapeutic tactics. Successful eradication of H. pylori in most cases depends on the optimal treatment regimen also has an impact on the result.

1 Matkivsky RA. Evaluation of the efectiveness of medical rehabilitation of children with chronic diseases of the digestive system. Medical almanac 2012; 2: 193-5
2 Sapozhnikov VG. Echography of the stomach and duodenum in children // Herald of new medical technologies (electronic journal) 2013; 1 Publication 2-146. URL: 3-1 /4596. pdf. (reference date is December 20, 2013)
3 Vorobyeva AV. On the problem of treatment of chronic gastroduodenitis in children. Bulletin of new medical technologies (electronic journal) 2013; 1 Publication 2-203. URL: 1/4670 . pdf (reference date is December 20, 2013)
4 Sapozhnikov VG, Vorobyova AV. Objective criteria for chronic diseases of the digestive organs in children. Bulletin of new medical technologies (electronic journal) 2015; 1 Publication 2-4. URL: 5 1/5062 . pdf (reference date is January 28, 2015). DOI: 10.12737/7593
5 Sapozhnikov VG. Helicobacter-associated gastro-duodenitis in children. Medical Newspaper 2014; 42: 9
6 Zryachkin NI, Chebotareva GI, Buchkova TN. Chronic gastritis and gastroduodenitis in children of preschool and school age (1st and 2nd parts). Questions of children»s dietology 2015; 4: 46-51; 5: 55-61
7 Zaprudnov AM, Grigoriev KI, Kharitonova LA, Bogomaz LV, Yudina TM. Problems and prospects of modern pediatric gas-troenterology. Pediatrics 2016; 6: 10-8
8 Parolova NI, Kornienko EA, Antonov PV, Egoro-va MB, Gorbunov EF, Dmitrienko MA. Innovative approach in the treatment of H. pylori infection in children. Russian Medical Journal 2015; 22: 1339-40
9 Fischbach W, Malfertheiner P. Helicobacter Pylori Infection. Dtsch Arztebl Int 2018; 115 (25): 429-36
10 Livzan MA. Post-eradication period of chronic gastritis associated with Helicobacter pylori. Consilium medicum 2010; 3: 36-40
11 Osadchuk MA, Zolotovitskaya AM, Kireeva NV, Niko-lenko SN, Kvetnoy IM. Clinical endoscopic and morphofunctional indicators in assessing the development of gastroesophageal refux disease in diferent age groups. Russian Journal of Gas-troenterology, Hepatology and Coloproctology 2012; 22 (5): 30-6
12 ApenchenkoYuS, Chervinets VM, Ivanova II, et al. Mi-crobiocenosis of the upper digestive tract in children with GERD and chronic gastroduodenitis. Clinical laboratory diagnostics 2013; 4: 40-3
13 Chernin VV, Bondarenko VM, Bazlov SN. Place of H. pylori and dysbacteriosis of the gastroduodenal zone in the etiology and pathogenesis of YB and CG. In: Multi-disciplinary approach to gastroenterological problems: theses of XXXIX session. Moscow, 2013; p. 49-50
14 O'Connor A, O'Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 2017; 14 (4): 230-40
15 Skvortsov VV. Topical issues of diagnosis and treatment of antral gastritis type B. Polyclinic 2012; 1: 1
16 Tobokhov AV, Nikolaev VN, Protopopova AI. Changes in the motility of the esophagus and stomach in certain pathological conditions of the stomach. Bulletin of the Eastern Scientifc Center of the Russian Academy of Medical Sciences 2012; 4 (86): 105-8
17 Zakharova IN, Osmanov IM, Pykov MI. Instrumental diagnosis of functional disorders of the gastrointestinal tract in the practice of a pediatrician and pediatric gastroenterologist. Consili-um Medicum: Pediatrics 2018; 1: 79-89
18 Brawner KM, Kumar R, Serrano CA. Helicobacter pylori infection is associated with an altered gastric microbiota in children. Mucosal Immunol 2017; 10 (5): 1169-77
19 Starostin BD. Treatment of Helicobacter infection: Maastricht V / Florence Consensus Report. Gastroenterology of St. Petersburg 2017; 1: 2-22
20 Hooi JKY, Lai WY, Wk N. Global prevalence of Helico-bacter pylori infection. Gastroenterology 2017: 1-10
21 Malfertheiner P., Megraud F., O»Morain C. A. Management of Helicobacter pylori infection: the Maastricht V / Florence Consensus Report. Gut 2017; 66 (1): 6-30
22 On approval of the standard of specialized medical care for children with gastric ulcer and duodenal ulcer: Order of the Ministry of Health of the Russian Federation of 07.11.2012 №638n. Moscow, 2012
23 On approval of the standard of specialized medical care for children with gastritis and duodenitis: Order of the Ministry of Health of the Russian Federation of 28.12.2012 №1598n. Moscow, 2012
24 Shcherbakov AP. Helicobacter pylori infection in children (recommendations of ESPGHAN and NASPGHAN 2010). The attending physician 2011; 6: 46-58
25 Standards for the diagnosis and treatment of acid-dependent and Helicobacter pylori-associated diseases (Fifth Moscow Agreement). In: Proceedings of the 13th Congress of the NGO. Moscow, 2013
26 Derkach VV. Possibilities of allergen-specifc im-munotherapy in the treatment of atopic dermatitis in children. Modern problems of science and education 2012; 2: 28
27 Zyryanov SK. Pharmacokinetics of medicines in children of diferent age groups. Medical technologies: Evaluation of choice 2011; 2: 70-6
28 Kornienko EA. Diagnosis and treatment of Helicobacter pylori infection in children in the light of the recommendations of international consensus Maastricht IV. Questions of children»s dietology 2013; 5: 73-9
29 Polunina ТV. Combined therapy of acid-dependent diseases. Russian Medical Journal 2013; 13: 25-9
30 Tkachenko EI. Optimization of treatment of diseases associated with Helicobacter pylori. The doctor 2012; 1: 36-8
31 Ivashkin VT, Maev IV, Lapina TL, Sheptulin AA, Trukhmanov AS, Abdulkhakov RA. Treatment of Helicobacter pylori infection: mainstream and novation. Russian Journal of Gastroenterology, Hepatology and Coloproctology 2017; 27 (4): 4-21
32 Bordin DS, Embutnieks YuV. Pathogenetic treatment of gastroesophageal refux disease: evidence base. Efective pharmacotherapy 2018 16: 8-13
33 Avvakumova NV, Chibiyeva LG, Vasilyev NN. Clinical and morphological characteristics of the gastric muco-sa in patients with acid-related diseases. Medical Sciences 2016; 3 (04): 8-10
34 Makhov VM, Turko ТV, Volodina ТV, Kulesh IA. Proton pump inhibitors are the main link in the treatment of acid-dependent pathology. Gastroenterology 2013; 13: 698-701
35 Rakitin B. V. Information about the consensus conference on the diagnosis and treatment of Helicobacter pylori infection Maastricht V: Report by M. Ley at the 42nd Scientifc Session of the TsNIIG, March 2-3, 2016
36 Kazyulin AN, Partsvania-Vinogradova EV, Dicheva DT. Optimization of antihelicobacter therapy in modern clinical practice. Consilium Medicum 2016; 8: 32-6
37 Simanenkov VI, Zakharova NV, Zhebrun AB, Svar-val AV, Savilova IV, Ferman RS. Helicobacter pylori resistance to antimicrobials based on bacteriological testing. Attending physician 2015; 4: 15-9
38 Maev IV, Andreev DN, Dicheva DT. Diagnosis and treatment of Helicobacter pillory infection: The provisions of the consensus Maastricht V (2015). Archive of internal medicine: Clinical guidelines 2017; 2: 85-94
39 Isaeva GSh. Helicobacter pylori resistance to antibacterial drugs and methods for its determination. Clinical microbiology and antimicrobial chemotherapy 2010; 1: 57-66
40 Jones NL, Koletzko S, Goodman K, et al. Joint ESP-GHAN / NASPGHAN Guidelines for the Management of Helico-bacter pylori in Children and Adolescents. J Pediatr Gastroenter-ol Nutr 2017; 64 (6): 991-1003
41 Sapozhnikov VG. Optimal scheme of anti-Helicobacter therapy in children: Selected materials of the XXII Congress of Children»s Gastroenterologists of Russia and CIS countries. Questions of children»s dietology 2015; 2: 82-3
42 Lapina TL, Tertychnyy AS, Nasretdinova ER. Results of long-term follow-up of patients with chronic gastritis after eradication of H. pylori infection. Russian Journal of Gastroen-terology, Hepatology and Coloproctology 2015; 4: 101-8
43 Kasiri KA, Khoshde Аl, Karimi А, Sedehi М, Kasi-ri N. Comparison of amoxicillin and metronidazole efect on three-drug regimen for the treatment of Helicobacter pylori infection in children. J Adv Pharm Technol Res. 2017; 8 (2): 63-6
44 Maev IV. The reasons for the inefectiveness of anti-Helicobacter therapy. Russian Journal of Gastroenter-ology, Hepatology, Coloproctology 2013; 6: 62-72
45 Akbulut UE, Fidan S, Emeksiz HC, Ors OP. Duodenal pathologies in children: a single-center experience. J Pediatr 2018; 94 (3): 273-8
46 Lapina TL, Tertychnyy AS, Pirogov SS. Dysplasia of the epithelium of the gastric mucosa in patients with chronic H. pylori-associated gastritis: is everything so clear? Russian Journal of Gastroenterology, Hepatology and Coloproctol-ogy 2015; 3: 90-101
47 Yazdanbod A, Salimian S, Habibzadeh S. Efect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. Arch Med Sci 2015; 5: 964-9
48 Shaikh T, Fallone C A. Efectiveness of second-through sixth-line salvage Helicobacter pylori treatment: Bismuth quadruple therapy is almost always a reasonable choice. Can J Gastro-enterol Hepatol 2015; 11: 17152
49 Diaconu S, Predescu A, Moldoveanu A, Pop CS, Fi-erbințeanu-Braticevici C. Helicobacter pylori infection: old and new. J Med Life 2017; 10 (2): 112-7
50 Uspensky YuP. Actual questions of diagnosis and treatment of diseases associated with Helico-bacter pylori infection. Polyclinic 2014; 2: 22-7
51 Uspensky YuP. Analysis of the World Data on He-licobacter pylori Resistance to Clarithromycin. Vestnik of practical doctor 2012; 2: 20-7
52 Осадчук М. М. Хеликобактериоз: Актуальные и нерешенные проблемы патогенеза и лечения. Практическая медицина 2012; 1 (56): 16-21
53 Нижевич А. А., Ахмадеева З. Н., Кучина Е. С., Сатаев В. У. Антихеликобактерная терапия у детей с хронической гастродуоденальной патологией: сравнение последовательной и «классической» схем лечения. Практическая медицина 2014; 1 (77): 65-7
54 Нижевич А. А., Усманова И. З., Еличева З. М., Ахмадеева Э. Н., Сатаев В. У. Факторы риска инфицирования Helicobacter pylo-ri-инфекцией у детей в Республике Башкортостан: роль HLA-антигенов. Вестник гематологии 2009; 4: 41-2
55 Ляликова Ю. В., Мирошниченко В. А., Тищенко Н. М. Распространенность генотипов VacA и CagA Helicobacter pylori у детей и взрослых города Владивостока. Современные проблемы науки и образования 2012; 4: 1-8
56 Levit MR, Spivak EM, Akkuratova IS. The efect of the persistence of Epstein — Barr infection on the infammatory process in the gastric mucosa and the efectiveness of anti-He-licobacter therapy in children with chronic gastroduodenitis. In: Topical problems of abdominal pathology in children: Materials of the Jubilee XX International Congress of Pediatric Gastroen-terologists of Russia and countries CIS. Moscow, 2013; p. 100-2
57 Spivak YeM, Levit RM, Akkuratova IS, Nadyozhin AS. Chronic gastroduodenitis in children: clinical options, diagnostic and treatment features. Yaroslavl: Filigran, 2016; 172 р.
58 Maev IV. Efect of polymorphism of the CYP2C19 gene on the efcacy of using proton pump inhibitors in the treatment of gastroesophageal refux disease. The attending physician 2011; 7: 93-5
59 Komarov FI, Rapoport SI. Guide to gastroenter-ology. Moscow: MIA, 2010; 864 p.

2019_02_225-231.pdf324.33 KB

No votes yet